Humanigen (HGENQ) Aandeel Koers
Humanigen Koers
De omzet is de afgelopen 13 jaar met 11,8% per jaar gegroeid tot 2,51 Miljoen USD. De nettowinstmarge van Humanigen ligt op -2.817,9% en is ten opzichte van -385,4% enkele jaren eerder gedaald.
Humanigen aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Humanigen bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Humanigen
The main competitors of Humanigen Inc in the market include pharmaceutical companies such as Eli Lilly and Company, Gilead Sciences Inc, and Regeneron Pharmaceuticals Inc.
Humanigen Inc is a biopharmaceutical company with a focus on advancing transformative monoclonal antibody therapeutics. Their business model revolves around developing and commercializing cutting-edge treatments to address unmet medical needs. Humanigen Inc utilizes its proprietary Humaneered® technology platform to create novel antibodies that target and neutralize disease-causing mechanisms in various diseases such as cancer and infectious diseases. Through strategic partnerships and collaborations, Humanigen Inc aims to bring innovative therapies to patients and improve their quality of life.
Humanigen Inc is primarily active in the biotechnology industry.
Humanigen Inc is a biopharmaceutical company specializing in developing and commercializing cutting-edge immunotherapies for various challenging diseases. Founded in 1997, Humanigen has a rich history in researching innovative treatments, including its proprietary Humaneered® antibody technology platform. With a focus on providing life-changing therapies, Humanigen strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's dedication to advancing science and delivering effective solutions has positioned Humanigen as a leader in the biopharmaceutical industry.
Humanigen Inc has achieved several significant milestones. One notable accomplishment is the development of their lead product candidate, lenzilumab. This innovative monoclonal antibody has shown promise in treating various diseases, including COVID-19 and CAR-T therapy-related side effects. Humanigen Inc has also made progress in advancing clinical trials for lenzilumab, with positive results demonstrating its potential efficacy. Furthermore, the company has secured partnerships and collaborations to further enhance their research and development efforts. These milestones highlight Humanigen Inc's commitment to driving advancements in healthcare and their dedication to improving patient outcomes.
Humanigen Inc is primarily present in the United States.
Humanigen Inc represents values of innovation, dedication, and patient-centered care. As a biopharmaceutical company, Humanigen is committed to developing cutting-edge therapies to address unmet medical needs. With a focus on precision medicine and next-generation solutions, the company aims to improve the lives of patients worldwide. Humanigen Inc's corporate philosophy is centered around scientific excellence, ethical conduct, and a mission-driven approach to transform healthcare. By leveraging its expertise and collaborative partnerships, Humanigen strives to offer effective and accessible treatments to patients while ensuring the highest standards of quality and safety.
8 analisten beoordelen het aandeel Humanigen momenteel: 0 adviseren kopen, 3 houden en 5 verkopen.
Het aandeel Humanigen (HGENQ) is genoteerd aan 4 beurzen, waaronder: NASDAQ (HGEN), Frankfurt (0KB2.F), München (0KB2.MU), Düsseldorf (0KB2.DU).
The company Humanigen Inc. is a biopharmaceutical company specializing in the development and marketing of treatments for rare and serious diseases. Its business model includes various sectors, including research and development, manufacturing and marketing of drugs, as well as research in collaboration with academic and nonprofit institutions.
De omzet kan momenteel niet worden berekend voor Humanigen.
De winst kan momenteel niet worden berekend voor Humanigen.
De P/E-ratio kan momenteel niet worden berekend voor Humanigen.
De P/S-ratio kan momenteel niet worden berekend voor Humanigen.
De Eulerpool Kwaliteitsscore voor Humanigen is 6/10.
De ISIN van Humanigen is US4448632038. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Humanigen is A2QEQW. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Humanigen is HGENQ. Onder dit beurstickersymbool wordt het Humanigen-aandeel op de beurs verhandeld.
Humanigen aandeel
Humanigen Peer Group
Humanigen Ticker
Humanigen FIGI
Alle fundamentals en diepgaande analyse van Humanigen
Onze aandelenanalyse van het Humanigen-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Humanigen. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: